ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Other Non Operating Income data on file, last reported at $2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 39.2% year-over-year to $2.0 million; the trailing twelve-month figure through Mar 2026 stood at -$1.3 million (down 110.83% YoY), and the FY2025 full-year result was $1000.0, down 99.99% from the prior year.
• Other Non Operating Income improved to $2.0 million in Q1 2026, from -$8.0 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $3.8 million in Q1 2023 to a low of -$8.9 million in Q4 2023.
• A 5-year average of $911235.3 and a median of $2.6 million in 2024 frame the typical range for Other Non Operating Income.
• Peak annual rise in Other Non Operating Income reached 6521.28% in 2023, while the deepest fall reached 872.79% in 2023.
• Tracing SPRY's Other Non Operating Income over 5 years: stood at $1.2 million in 2022, then plunged by 872.79% to -$8.9 million in 2023, then surged by 133.92% to $3.0 million in 2024, then plunged by 364.73% to -$8.0 million in 2025, then surged by 124.58% to $2.0 million in 2026.
• Business Quant data shows SPRY's Other Non Operating Income at $2.0 million in Q1 2026, -$8.0 million in Q4 2025, and $2.0 million in Q3 2025.